Targeted Protein Degradation (TPD) has created a paradigm shift and emerged as a front-runner in drugging many "undruggable" targets. As a new modality, it poses unique challenges for lead discovery as well as API development and manufacturing.
We will focus on the latest advances in chemical building blocks for protein degradation, including warheads, linkers, and ligands, and how they can be used to build better degraders. Once a candidate has been identified, selection of the right CDMO can take a phase-appropriate approach to develop with commercial readiness in mind, provide partnered quality and regulatory support, and offer batch scalability as you progress through the clinic.
In this webinar, you will learn about:
- Targeted Protein Degradation (TPD) technologies
- A mechanistic view of this new modality
- Chemical advancements for modular and strategic degrader design
- How to select the appropriate contract manufacturing partner
Speakers
Aditya S. Vaidya
Chemical Biology Innovation
Senior Scientist
Aditya Vaidya is a senior scientist in the Chemical Biology Innovation Team at SLS Chemistry. His work focuses on creating innovative solutions for the chemical biology and drug discovery community, including novel tools for targeted protein degradation, which is considered the next gold rush in drug discovery. He is dedicated to providing cutting-edge products that can revolutionize drug discovery and lead to improvements in human health. Aditya holds a Ph.D. in medicinal chemistry from the University of Illinois at Chicago and has over 10 years of experience in the field of drug discovery.
Hugo Matos Viana
MilliporeSigma
Global Product Manager - Chemical Biology
Hugo Matos Viana is a life science professional with extensive technical and business expertise in Chemistry. In his current role, he is responsible for overseeing the Chemical Biology portfolio strategy at Merck KGaA, Darmstadt, Germany. Hugo holds a PhD in Organic Chemistry and is attending an Executive MBA program.
Jason Modest
MilliporeSigma
Director of Manufacturing, Science and Technology
Jason Modest has been in the pharmaceutical industry for 25 years and is the director of the manufacturing, science, and technology department at the Madison/Verona, WI site. He leads the technical transfer and validation teams and provides life cycle management for commercial programs. Transitioning into technical operations positions in brand, generic, and the CDMO space has allowed for a comprehensive understanding of what is required to successfully move early-phase development programs to commercial launch. Jason holds a B.S. in biochemistry from Fort Lewis College.
Jacqueline Ruff
MilliporeSigma
Strategic Marketing Manager
Jacqueline Ruff is a strategic marketing manager leading marketing initiatives for the growing small molecule CTDMO landscape at MilliporeSigma. Prior to joining the marketing franchise, she gained experience in small molecule CDMO operations through her roles in project management and quality management. Jackie received bachelor's degrees in both genetics and life science communication at the University of Wisconsin, and her Master's in biotechnology enterprise and entrepreneurship from Johns Hopkins University.
Pharma and biopharma manufacturing
- Detecting & Removing Aggregates
Durée:1h
Langue:English
Session 1:présenté(e) June 15, 2023
Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.
Vous n'avez pas de compte ?